Although downmodulation of RRM2 by synthetic means (e.g., siRNA) has shown potential in decreasing tumor growth and gemcitabine chemoresistance, the possibilities of manipulating endogenous molecules to improve gemcitabine responses and perhaps improving therapeutic outcomes in pancreatic cancer have never been explored. The gene discussed is RRM2; the disease is neoplasm.